Anti-thymocyte globulin (Stanford University)

N/A

Report date: 2022/11/20 15:38:00

Base Information

Drug NameAnti-thymocyte globulin (Stanford University)
Drug Alias Name抗胸腺细胞球蛋白-斯坦福大学
ClassificationBiologics > Blood components
Mechanisms of ActionImmunosuppressants
TargetsNot applicable
Therapy Area/IndicationsSezary SyndromeLymphoma, T-Cell, CutaneousLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesStanford University
Inactive CompaniesN/A
Active IndicationsSezary SyndromeLymphoma, T-Cell, CutaneousLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A